New study provides insight into asthma hospitalizations in PA
(WJET/WFXP) – One Pennsylvania council is hoping to learn more about a common lung disease through its newest research.
On Thursday, May 15, the Pennsylvania Health Care Cost Containment Council (PHC4) published a research study titled 'Asthma Hospitalizations in Pennsylvania.'
Meadville company pays over $64K for 2024 teen finger amputation incident
The study focused on the hospitalization of Pennsylvania residents who were later diagnosed with asthma, providing insight into the most common age groups, sexes, races/ethnicities and counties of those patients.
According to the study, the PHC4 found hospitalization rates to be highest for:
Residents who were less than 18 years old
Female residents
Black (non-Hispanic) residents, Hispanic residents, and residents classified as Other (non-Hispanic)
Residents who live in areas with a poverty rate of 10% or more
Residents who live in urban counties
The executive director of PHC4, Barry D. Buckingham, said that conducting studies like these is imperative to providing better care in the future.
UPMC Hamot honored with Beacon Awards for Excellence
'Examining hospital admissions for asthma is one way to observe the quality of care provided to Pennsylvania residents with asthma. This type of reporting adds to the resources used to effectively reduce and prevent asthma-related hospitalizations,' said Buckingham.
Those interested in reading the full study can do so by clicking here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.
Miami Herald
16 hours ago
- Miami Herald
Changemakers and moneymakers: Nonprofits meet with funders for community change
Ashley Eubanks Johnson never imagined she would find her calling on a highway off-ramp. While commuting home from work one evening in 2016, a homeless woman weaved through cars at a Pompano Beach stoplight to ask for change, her pants stained with blood due to her period. 'That really shocked me because the area we were in was down the street from a shelter,' admitted a now-38-year-old Eubanks Johnson. '[I] started calling around to different shelters, facilities and organizations that serve those that are unhoused and found little to no help or refuge for menstruators in need.' Shortly after, she took the money set aside for her 30th birthday trip to Jamaica and kickstarted The Beauty Initiative, a nonprofit that donates hygiene essentials like pads and tampons to women and girls in need. READ MORE: Nonprofit provides homeless women with help — and free sanitary hygiene items In the years since, Eubanks Johnson has revolutionized period-care awareness in greater Miami, touting her nonprofit's donation of 77,000 menstrual-care products to Miami-Dade County and Broward County schools this academic year, but the road to success has been bumpy. She has had to juggle her day job as a community liaison and database administrator for Broward County Public Schools alongside her community work for nearly a decade, occasionally dipping into her own paychecks to support the cause. 'I've done this work for almost nine years with no money, my money, and now some sponsorship money,' shares the Beauty Initiative CEO. Neglecting local grassroots nonprofits is an oversight that the world of philanthropy and one Miami-based organization are hoping to remedy. Changemakers and moneymakers A self-professed 'social impact accelerator,' Radical Partners' mission is to equip South Florida changemakers with the skills and funds needed to run a nonprofit and deploy them into their communities. The organization, which was established in 2012, pushes professional development and organizational management as part of the solution through initiatives such as Leadership Labs, a five-month program tailored to leaders who identify as Black, Indigenous or people of color. The other part of the solution? Rubbing elbows with moneymakers. In a Neighborhood Heroes Connect conference hosted by Radical Partners at the Phillip & Patricia Frost Museum of Science in Miami on June 5, The Beauty Initiative and other nonprofits met with JPMorgan Chase, TD Bank and other corporations to discuss the gaps in grassroots-nonprofit financing. Study findings released at the conference on the impact of Leadership Labs, whose curriculum promises networking opportunities with leaders in the nonprofit, for-profit and political sectors, revealed that the relationship between those funded and those funding is interdependent. Results from a survey conducted by Radical Partners showed that the improvements that nonprofits sought most aligned with what funders hoped to invest in. While most surveyed organizations reported fundraising, grant-writing help and optimized operational systems among their highest needs, funders reported innovative fundraising efforts and strong daily operations as the most attractive qualities when considering which groups to finance. 'There are things that you can achieve at a neighborhood level, where there's more trust and where, culturally, people understand the individuals they're working with,' said Ana Castillo, TD Bank's Florida regional community development manager. Castillo leverages her role to give marginalized communities in South Florida more access to traditional banking so they don't have to resort to risky financial moves such as payday loans. She says TD Bank's mission is accomplished, in part, by funding local organizations that understand their underserved neighborhoods best. Meanwhile, nonprofits such as the Foot Forward Foundation, founded by Broward-based Christopher Sisco and Maurizo Raponi, benefit from the spotlight that tends to follow funders. '[We want] just a little bit of visibility,' said Sisco, 41, who began the initiative in 2022 by handing out shoes from his own 'sneakerhead' collection to homeless people. The nonprofit has since expanded to serve low-income students and has launched six shoe-donation campaigns at schools across Broward and Miami-Dade in the past 18 months. 'We do what we do because we enjoy doing it, but [we hope] for more people with big pockets to see what Foot Forward is doing.' Creative solutions Championing collaboration between funders and nonprofit leaders, Radical Partners CEO Joana Godoy proposes what her organization calls 'creative solutions' to long-standing obstacles in the nonprofit sector. To alleviate the disparity between funders' donation caps and nonprofits' need for resources, Godoy suggests nonprofits share services and spaces — such as collectively pitching in for an accountant or having joint office areas — to spur teamwork while cutting costs. How to streamline administrative work when short-staffed? She recommends nonprofits look to how the business world has used artificial intelligence. 'We might die trying [to implement these solutions alone],' urged Godoy. 'So what we're offering here is, instead of putting everything on [ourselves], meaning 'my team, my organization, my funders,' for us to approach it as an ecosystem.' It's an outlook that changemakers such as Eubanks Johnson, who graduated from Leadership Labs' third cohort in 2019, have already begun to adopt and benefit from. '[Radical Partners gives] us the tools we need to lead, connects us with a community of trusted collaborators and . . . [helped me] lean into my gifts and trust myself,' shared Eubanks Johnson. 'With doing that, I was able to center my work in service with so many others.'
UPI
17 hours ago
- UPI
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.
